The biggest impediment to script growth until now has probably been the step-edits and prior-authorization requirements that posters on this board have complained about.
Zuman and Dew, the prescription growth will screech to a halt very shortly if Amarin doesn't find a way to keep Vascepa on the "Covered Drugs" lists of major Pharmaceutical Managers. My research is showing me that more and more Formularies have had Vascepa removed and the suggested replacement is Lovaza. Amarin has not addressed this except to say they have Tier Status through November 2014. What about 2015 guys? This is becoming more critical every day!
News 
Market Data 
Discover 
